CytoDyn(CYDY)

Focus: CytoDyn is a public-stage biotechnology company headquartered in Vancouver, WA, focused on monoclonal antibody therapeutics targeting infectious diseases, oncology, and inflammatory conditions. The company operates as a clinical-stage biotech with a diversified pipeline spanning multiple therapeutic areas.

Infectious Diseases Oncology Oncology, Inflammation Chemistry, Manufacturing and Control

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About CytoDyn

AI assessmentNot Hiring

No open roles listed right now. Follow CytoDyn to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PRO 140

HIV

N/A

Clinical Trials (1)

NCT02759042An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

N/A

Help build intelligence for CytoDyn

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline with 25 active clinical programs across HIV, COVID-19, oncology, and inflammatory indications—exposure to multiple therapeutic areas
Public company status provides liquidity and equity upside potential, with ticker CYDY offering transparency into clinical progress
Focused monoclonal antibody platform allows deep specialization in a validated, high-value modality with broad application

Watch Out For

Severe cash constraint: only $3M cash on hand (FY 2025) against $49.8M net loss, creating acute runway risk and restructuring probability
Only 2 active job openings despite 25 clinical programs suggests organizational contraction or recruitment freeze during liquidity crisis
No approved products generating revenue and minimal R&D spend ($3M in FY 2024) relative to net losses, indicating limited resources for clinical advancement

Generated by Claude from CytoDyn's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Observational Study of Blood Treated With Cytolin

HIV Infections

N/A

Clinical Trials (1)

NCT01048372Observational Study of Blood Treated With Cytolin

N/A

Leronlimab

Metastatic Triple-Negative Breast Carcinoma

N/A

Clinical Trials (1)

NCT04313075A Compassionate Use Study of Leronlimab in Breast Cancer

N/A

PRO 140

HIV Infections

PHASE_1

Clinical Trials (2)

NCT00110591Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

Phase 1

NCT07536815An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

N/A

350 mg leronlimab

Triple Negative Breast Neoplasms

PHASE_1_2

Clinical Trials (1)

NCT03838367Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

Phase 1/2

PRO 140

HIV

PHASE_2

Clinical Trials (1)

NCT01272258A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

Phase 2

700mg leronlimab weekly dose

CCR5

PHASE_2

Clinical Trials (1)

NCT05730673Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Phase 2

Placebos

Coronavirus Disease 2019

PHASE_2

Clinical Trials (1)

NCT04678830Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

Phase 2

Placebo

Coronavirus Disease 2019

PHASE_2

Clinical Trials (1)

NCT04347239Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

Phase 2

Placebo

Coronavirus Disease 2019

PHASE_2

Clinical Trials (1)

NCT04343651Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

Phase 2

PRO 140

HIV

PHASE_2

Clinical Trials (1)

NCT02175680Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

Phase 2

PRO 140

HIV -1 Infection

PHASE_2

Clinical Trials (1)

NCT00642707Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

Phase 2

PRO 140 350mg weekly subcutaneous

HIV

PHASE_2

Clinical Trials (1)

NCT02355184An Extension of Protocol PRO 140_CD01 Study

Phase 2

PRO 140

HIV Infections

PHASE_2

Clinical Trials (1)

NCT00613379PRO 140 by IV Administration in Adults With HIV-1 Infection

Phase 2

PRO 140

Graft Vs Host Disease

PHASE_2

Clinical Trials (1)

NCT02737306A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

Phase 2

350 mg leronlimab

Metastatic Colorectal Cancer (mCRC)

PHASE_2

Clinical Trials (1)

NCT06699836The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)

Phase 2

Placebo

Nonalcoholic Steatohepatitis (NASH)

PHASE_2

Clinical Trials (1)

NCT04521114Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

Phase 2

Leronlimab

Solid Tumor, Adult

PHASE_2

Clinical Trials (1)

NCT04504942Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Phase 2

PRO 140

Human Immunodeficiency Virus (HIV)

PHASE_2_3

Clinical Trials (1)

NCT02990858An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study

Phase 2/3

PRO 140

HIV-1-infection

PHASE_2_3

Clinical Trials (1)

NCT03902522PRO 140 in Treatment-Experienced HIV-1 Subjects

Phase 2/3

PRO 140

HIV

PHASE_2_3

Clinical Trials (1)

NCT02483078Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140

Phase 2/3

PRO 140

HIV

PHASE_2_3

Clinical Trials (1)

NCT02859961Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

Phase 2/3

PRO 140 350

HIV-1-infection

PHASE_2_3

Clinical Trials (1)

NCT05271370An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Phase 2/3

Leronlimab

COVID-19 Pneumonia

PHASE_3

Clinical Trials (1)

NCT04901676Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia

Phase 3

Leronlimab

COVID-19 Pneumonia

PHASE_3

Clinical Trials (1)

NCT04901689Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

Phase 3